File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Overexpression of p53 in hepatocellular carcinomas: A clinicopathological and prognostic correlation

TitleOverexpression of p53 in hepatocellular carcinomas: A clinicopathological and prognostic correlation
Authors
Issue Date1995
Citation
Journal Of Gastroenterology And Hepatology, 1995, v. 10 n. 3, p. 250-255 How to Cite?
AbstractOverexpression of the p53 tumour suppressor gene is one of the most common abnormalities in primary human cancers and appears to be a result of point mutation within a highly conserved region of the gene with subsequent encoding for a mutant, more stable, protein. In this study, 71 surgically resected hepatocellular carcinomas (HCC) were examined to study the expression of the p53 gene, its relation with clinicopathological parameters and its prognostic significance. Using immunohistochemical detection for mutant p53 protein with monoclonal antibody PAb1801, p53 overexpression was found in 22 tumours (31%) but in none of the non-tumorous liver specimens. Overexpression of p53 was more frequent in tumours with poor cellular differentiation (P = 0.01), in tumours > 5 cm in diameter (P = 0.05), and in those with giant cells present (P = 0.03) and, less significantly, of massive type of Eggel's classification (P = 0.06). It did not have any significant correlation with hepatitis B or C status, background liver disease or serum α-fetoprotein levels, nor was it related to tumour invasiveness (venous permeation, direct liver invasion and tumour microsatellite formation). In addition, the presence of p53 mutant protein did not influence tumour recurrence or patients' survival rates. The data suggested that p53 mutation in HCC was associated with a later stage of oncogenesis. However, it was not apparently related to tumour invasiveness/aggressiveness and prognosis.
Persistent Identifierhttp://hdl.handle.net/10722/148045
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNg, IOLen_US
dc.contributor.authorLai, ECSen_US
dc.contributor.authorChan, ASYen_US
dc.contributor.authorSo, MKPen_US
dc.date.accessioned2012-05-29T06:10:33Z-
dc.date.available2012-05-29T06:10:33Z-
dc.date.issued1995en_US
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 1995, v. 10 n. 3, p. 250-255en_US
dc.identifier.issn0815-9319en_US
dc.identifier.urihttp://hdl.handle.net/10722/148045-
dc.description.abstractOverexpression of the p53 tumour suppressor gene is one of the most common abnormalities in primary human cancers and appears to be a result of point mutation within a highly conserved region of the gene with subsequent encoding for a mutant, more stable, protein. In this study, 71 surgically resected hepatocellular carcinomas (HCC) were examined to study the expression of the p53 gene, its relation with clinicopathological parameters and its prognostic significance. Using immunohistochemical detection for mutant p53 protein with monoclonal antibody PAb1801, p53 overexpression was found in 22 tumours (31%) but in none of the non-tumorous liver specimens. Overexpression of p53 was more frequent in tumours with poor cellular differentiation (P = 0.01), in tumours > 5 cm in diameter (P = 0.05), and in those with giant cells present (P = 0.03) and, less significantly, of massive type of Eggel's classification (P = 0.06). It did not have any significant correlation with hepatitis B or C status, background liver disease or serum α-fetoprotein levels, nor was it related to tumour invasiveness (venous permeation, direct liver invasion and tumour microsatellite formation). In addition, the presence of p53 mutant protein did not influence tumour recurrence or patients' survival rates. The data suggested that p53 mutation in HCC was associated with a later stage of oncogenesis. However, it was not apparently related to tumour invasiveness/aggressiveness and prognosis.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma, Hepatocellular - Genetics - Mortality - Pathologyen_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene Expressionen_US
dc.subject.meshGenes, P53en_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshLiver Neoplasms - Genetics - Mortality - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshSurvival Rateen_US
dc.subject.meshTumor Suppressor Protein P53 - Analysis - Biosynthesisen_US
dc.titleOverexpression of p53 in hepatocellular carcinomas: A clinicopathological and prognostic correlationen_US
dc.typeArticleen_US
dc.identifier.emailNg, IOL:iolng@hkucc.hku.hken_US
dc.identifier.authorityNg, IOL=rp00335en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid7548799-
dc.identifier.scopuseid_2-s2.0-0029041691en_US
dc.identifier.volume10en_US
dc.identifier.issue3en_US
dc.identifier.spage250en_US
dc.identifier.epage255en_US
dc.identifier.isiWOS:A1995RC02600004-
dc.publisher.placeAustraliaen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats